Feasibility and efficacy of a weight gain prevention intervention for breast cancer patients receiving neoadjuvant chemotherapy: a randomized controlled pilot study

Basen-Engquist, Karen; Raber, Margaret; Carmack, Cindy L.; Arun, Banu K.; Brewster, Abenaa M.; Fingeret, Michelle Cororve; Schembre, Susan M.; Harrison, Carol; Perkins, Heidi Y.; Li, Yisheng; Song, Jaejoon; Chen, Minxing; Murray, James L.

doi:10.1007/s00520-020-05411-2

Cited by 20 publications

(24 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In general, patients with breast cancer gain weight during chemotherapy, which often persists in the years following completion of treatment [36][37][38]. Weight gain can lead to poor QoL, physiological stress and body image issues [39,40].…”

Section: Discussionmentioning

confidence: 99%

Quality of life and illness perceptions in patients with breast cancer using a fasting mimicking diet as an adjunct to neoadjuvant chemotherapy in the phase 2 DIRECT (BOOG 2013–14) trial

Lugtenberg

Groot

Kaptein

et al. 2020

Breast Cancer Res Treat

View full text Add to dashboard Cite

Purpose In the phase II DIRECT study a fasting mimicking diet (FMD) improved the clinical response to neoadjuvant chemotherapy as compared to a regular diet. Quality of Life (QoL) and illness perceptions regarding the possible side effects of chemotherapy and the FMD were secondary outcomes of the trial. Methods 131 patients with HER2-negative stage II/III breast cancer were recruited, of whom 129 were randomly assigned (1:1) to receive either a fasting mimicking diet (FMD) or their regular diet for 3 days prior to and the day of neoadjuvant chemotherapy. The European Organisation for Research and Treatment of Cancer (EORTC) questionnaires EORTC-QLQ-C30 and EORTC-QLQ-BR23; the Brief Illness Perception Questionnaire (BIPQ) and the Distress Thermometer were used to assess these outcomes at baseline, halfway chemotherapy, before the last cycle of chemotherapy and 6 months after surgery. Results Overall QoL and distress scores declined during treatment in both arms and returned to baseline values 6 months after surgery. However, patients’ perceptions differed slightly over time. In particular, patients receiving the FMD were less concerned and had better understanding of the possible adverse effects of their treatment in comparison with patients on a regular diet. Per-protocol analyses yielded better emotional, physical, role, cognitive and social functioning scores as well as lower fatigue, nausea and insomnia symptom scores for patients adherent to the FMD in comparison with non-adherent patients and patients on their regular diet. Conclusions FMD as an adjunct to neoadjuvant chemotherapy appears to improve certain QoL and illness perception domains in patients with HER2-negative breast cancer. Trialregister ClinicalTrials.gov Identifier: NCT02126449.

show abstract

Section: Discussionmentioning

confidence: 99%

Quality of life and illness perceptions in patients with breast cancer using a fasting mimicking diet as an adjunct to neoadjuvant chemotherapy in the phase 2 DIRECT (BOOG 2013–14) trial

Lugtenberg

Groot

Kaptein

et al. 2020

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…Souza et al 27 showed that nutritional interventions improved patients' grip strength, positively affected the occurrence of nausea/vomiting and loss of appetite, and reduced the frequency of leucopenia and abdominal pain during NAC. Basen-Engquist et al 28 reported that weight gain prevention intervention reduced more in waist circumference (p=0.03) and greater improvements in self-reported vitality scores (p=0.03) compared with the control group. The majority of participants reported being satisfied with the intervention during chemotherapy (88%).…”

Section: Resultsmentioning

confidence: 99%

“… 30 Two studies were each from Brazil 25 27 and Korea, 21 31 and one each from China, 20 Japan, 29 India, 22 UK, 26 Germany, 23 Indonesia, 30 Iran 24 and the USA. 28 One study compared QOL in BC patients with NAC and adjuvant therapy, 25 and three studies compared QOL in patients with different regimens of NAC. 22 24 26 Two studies were in the same clinical trial registration with different included subjects.…”

Section: Resultsmentioning

confidence: 99%

Quality of life in patients with breast cancer with neoadjuvant chemotherapy: a systematic review

et al. 2022

View full text Add to dashboard Cite

ObjectivesThe aims of this systematic review were to assess the impact of neoadjuvant chemotherapy (NAC) on breast cancer (BC) patients’ quality of life (QOL), to compare the different regimens of NAC on BC patients’ QOL, to compare NAC versus adjuvant chemotherapy on BC patients’ QOL and to identify predictors of QOL on patients with BC receiving NAC.DesignThe design used Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.Data sourcesCinahl, Embase, Pubmed, Scopus, Web of Science, Cochrane library and PsycINFO were searched through 27 December 2021.Eligibility criteria for selecting studiesThe inclusion criteria were included: patients with BC receiving NAC, outcome measures related to QOL and published in English. The exclusion criteria were included: duplicates or overlapping participants, not original research, data or full text not available and qualitative study.Data extraction and synthesisTwo independent reviewers used standardised methods to search, screen and code included studies. The risk of bias in individual studies was evaluated with Cochrane collaboration’s tool for assessing risk bias, Newcastle Ottawa Score or Joanna Briggs Institute Critical Appraisal tool. This systematic review performs narrative synthesis based on several different themes.ResultsThe initial search resulted in 2994 studies; 12 of these studies fulfilled inclusion criteria. There was no significant difference in the QOL of BC before and after NAC, but patients experienced adverse reactions and depression during chemotherapy. Different regimens of NAC have different effects on patients’ QOL. Patients with NAC had more severe physical discomfort than those with adjuvant chemotherapy. However, BC patients’ QOL can be improved by intervening on social or family support, and these predictors, including chronotype, QOL before NAC and depression.ConclusionsMore original research is needed in future to understand the profile and predictors of QOL in patients with BC on NAC, which will help clinicians and patients make decisions and deal with NAC-related issues.

show abstract

“…First, inclusion of only randomized controlled trials may have led us focus on efficacy trials in academic settings and miss pragmatic trials in clinical settings, including those stimulated by the COVID-19 pandemic. Although there were eleven articles published between 2020 and 2021 [ 32 , 37 , 41 , 46 , 50 , 62 , 71 , 76 , 80 , 84 , 90 ], no articles took place during or referenced the COVID-19 pandemic. Future research should consider differences among pre-, during-, and post-pandemic telehealth-based cancer rehabilitation intervention research in terms of populations reached, functional measures used and associated outcomes, as well as technology platforms utilized.…”

Section: Discussionmentioning

confidence: 99%

The influence of telehealth-based cancer rehabilitation interventions on disability: a systematic review

et al. 2022

View full text Add to dashboard Cite

Purpose To characterize delivery features and explore effectiveness of telehealth-based cancer rehabilitation interventions that address disability in adult cancer survivors. Methods A systematic review of electronic databases (CINAHL Plus, Cochrane Library: Database of Systematic Reviews, Embase, National Health Service’s Health Technology Assessment, PubMed, Scopus, Web of Science) was conducted in December 2019 and updated in April 2021. Results Searches identified 3,499 unique studies. Sixty-eight studies met inclusion criteria. There were 81 unique interventions across included studies. Interventions were primarily delivered post-treatment and lasted an average of 16.5 weeks ( SD = 13.1). They were most frequently delivered using telephone calls (59%), administered delivered by nursing professionals (35%), and delivered in a one-on-one format (88%). Risk of bias of included studies was primarily moderate to high. Included studies captured 55 measures of disability. Only 54% of reported outcomes had data that allowed calculation of effect sizes ranging -3.58 to 15.66. Conclusions The analyses suggest small effects of telehealth-based cancer interventions on disability, though the heterogeneity seen in the measurement of disability makes it hard to draw firm conclusions. Further research using more diverse samples, common measures of disability, and pragmatic study designs is needed to advance telehealth in cancer rehabilitation. Implications for Cancer Survivors Telehealth-based cancer rehabilitation interventions have the potential to increase access to care designed to reduce disability across the cancer care continuum. Supplementary Information The online version contains supplementary material available at 10.1007/s11764-022-01181-4.

show abstract

Feasibility and efficacy of a weight gain prevention intervention for breast cancer patients receiving neoadjuvant chemotherapy: a randomized controlled pilot study

Cited by 20 publications

References 48 publications

Quality of life and illness perceptions in patients with breast cancer using a fasting mimicking diet as an adjunct to neoadjuvant chemotherapy in the phase 2 DIRECT (BOOG 2013–14) trial

Quality of life and illness perceptions in patients with breast cancer using a fasting mimicking diet as an adjunct to neoadjuvant chemotherapy in the phase 2 DIRECT (BOOG 2013–14) trial

Quality of life in patients with breast cancer with neoadjuvant chemotherapy: a systematic review

The influence of telehealth-based cancer rehabilitation interventions on disability: a systematic review

Contact Info

Product

Resources

About